- Investing Ideas
- Taiwanese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Taiwanese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Caliway Biopharmaceuticals
Market Cap: NT$167.3b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$107.50
7D
4.4%
1Y
-17.3%
PharmaEssentia
Market Cap: NT$531.8b
A biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan.
6446
NT$1,290.00
7D
25.9%
1Y
211.4%